Asthma Clinical Trial
Official title:
Primary Prevention of Atopic Disease by Perinatal Administration of Probiotics.
Administration of probiotics to pregnant women from an atopic family and subsequently to their high-risk newborns results in prevention of the incidence or in a decrease of the severity of atopic disease during infancy.
Background. Atopic diseases are increasing in countries with a Western lifestyle. The
hygiene hypothesis states that the increase in atopic disease could be due to reduced
exposure to microbial antigens in early in life. In search of new preventive therapies for
atopic disease, exposure of pregnant women with previous or recent atopic disease, and their
offspring to probiotics has been suggested. Probiotics are mono or mixed cultures of
microbes which, when applied to animal or man, can beneficially affect the host, among
others by inducing an immune response. Probiotics are generally accepted to be safe in
children. Probiotics have shown to be effective in primary prevention of atopic disease in
high-risk neonates in one study so far. However, it is still unclear by what mechanism
probiotics work and which is the most immunopotent (combinations of) probiotic(s). It is
likely that antigen-presenting cells (APC's) are involved, since these cells are important
in the first line of defence in the gastrointestinal tract. It can be imagined that the
immune response is the result of the interplay between probiotics and APC's. In particular,
the match between pathogen-associated molecular patterns (PAMP's) on probiotics and their
counterparts on APC's, the pathogen-recognition-receptors (PRR's) (like for instance
Toll-like receptors) is decisive in this aspect.
Hypothesis. Administration of probiotics to pregnant women and their offspring may reduce
the development of sensitization as well as the onset of atopic disease in their offspring.
Aim. To study the effect of probiotics on sensitisation and the prevalence of atopic
disease, the severity of atopic disease, the intestinal flora and immune parameters in
high-risk newborns.
Methods. To study this hypothesis, a randomised, double-blind placebo-controlled trial will
be carried out by administration of probiotics to pregnant women with previous or recent
atopic disease as well as to their offspring. Primary outcome parameters are firstly the
prevalence and severity of sensitization and atopic disease in the offspring during a
follow-up of two years. Secondary outcome parameters are the change in stool composition
during treatment with probiotics and in-vitro production of cytokines by PBMCs collected at
3 months, 1 year and 2 years of age.
Expected results. Perinatal administration of probiotics to pregnant women and their
offspring may hamper the development of sensitization and atopic disease in their offspring.
This may be due to modulation of the intestinal microbiota composition, and modulation of
the developing immune system
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|